Evidence map›Paper›PMID 41836414›Full record

ArticleFrontiers in immunology2026

A functional cell model using basophil activation test to study molecular mechanisms and biomarkers of response to omalizumab treatment in patients with asthma.

Boris Gole, Larisa Goričan, Gregor Jezernik, Mario Gorenjak, Anja Bizjak, Vojko Berce, Maja Skerbinjek Kavalar, Michael Kabesch, Erik Melén, Korneliusz Golebski and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Boris GoleCenter for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
Larisa GoričanCenter for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
Gregor JezernikCenter for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
Mario GorenjakCenter for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
Anja BizjakCenter for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
Vojko BerceCenter for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
Maja Skerbinjek KavalarAmbulanta Čebelica, Maribor, Slovenia.
Michael KabeschDepartment of Pediatric Pneumology and Allergy, University Children's Hospital Regensburg (KUNO), Regensburg, Germany.
Erik MelénDepartment of Clinical Sciences and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Korneliusz GolebskiDepartment of Pulmonary Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Cornelius M van DrunenDepartment of Otorhinolaryngology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Anke Hilse Maitland-van der ZeeDepartment of Pulmonary Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Susanne ReinartzDepartment of Otorhinolaryngology, Tergooi Hospitals, Hilversum, Netherlands.
Susanne J H VijverbergDepartment of Pulmonary Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Uroš PotočnikCenter for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Maribor, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with severe asthma may benefit from targeted biological therapies. However, personalized therapy in children and adolescents with asthma, based on individual susceptibility to molecular mechanisms addressed by different biologicals is underdeveloped. Here, we established a functional Methods: White blood cells isolated from asthmatic children and adolescents were pre-treated with omalizumab. Next, basophil activation and degradation were used to assess the Results: The Conclusions: We describe an

Indexed as

Anti-Asthmatic AgentsAsthmaBasophilsOmalizumabAdolescentBiomarkersChildFemaleHumansImmunoglobulin EMaleTreatment OutcomeAnti-Asthmatic AgentsBiomarkersImmunoglobulin EOmalizumabbasophil activationbiomarkerdifferential response to omalizumabin vitro cell modelpediatric asthmaprecision medicinetranscriptomics

Identifiers

PMID41836414
PMCPMC12982396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.